3646 results for «687»
3646 results
Innovations in structural interventions
20 May 2026 – From EuroPCR 2026
Highlighting the forefront of structural heart interventions, this session presents innovations including novel devices and technologies from industry leaders. It features advancements such as a new transseptal left atrial fixation device designed to expand the suitability of transcatheter mitral valve replacement (TMVR).
Imaging to the rescue in LAA closure
20 May 2026 – From EuroPCR 2026
This session highlights the pivotal role of advanced imaging modalities in left atrial appendage (LAA) closure. Topics include novel risk assessment workflows for air embolism, evaluation protocols using cardiac CT and 3D TEE, reproducibility of anatomical classifications, and long-term follow-up outcomes with various imaging techniques.
Navigating the complexity of high bleeding risk
20 May 2026 – From EuroPCR 2026
Focusing on patients with high bleeding risk undergoing PCI, this session presents contemporary evidence on prevalence, procedural strategies with different stent types, antiplatelet therapy considerations including diabetic and sex-specific outcomes, and novel technologies such as sirolimus-coated balloons and machine learning models for restenosis prediction.
Registries and trials in TMVR
20 May 2026 – From EuroPCR 2026
This session provides an in-depth review of registries and clinical trials focused on transcatheter mitral valve replacement (TMVR). It presents data on annular and ventricular remodeling with the HighLife system, mid- to long-term valve performance, and innovations in transseptal TMVR using novel bioprostheses.
Pivotal study on the ShortCut transcatheter aortic valve leaflet splitting device
16 May 2024
Coronary obstruction is a major concern in patients undergoing TAVI for degenerated bioprostheses (valve-in-valve [ViV]) and is associated with a 30-day mortality rate of around 50%.1 While several transcatheter techniques to lacerate bioprosthetic valve leaflets prior to TAVI placement (such as BASILICA) have been described, they are...
GLORIOUS - Efficacy of restrictive versus liberal oxygenation or Exenatide in patients undergoing coronary artery bypass grafting or aortic valve replacement – a randomised clinical trial
21 Nov 2024
Edoardo Zancanaro provides his take on the GLORIOUS trial presented by Sebastian Wiberg at AHA 2024 in Chicago.
Author
